Peripheral Neuropathy Market Report 2026

Peripheral Neuropathy Market Overview

• Peripheral Neuropathy market size has reached to $4.59 billion in 2025 • Expected to grow to $7.98 billion in 2030 at a compound annual growth rate (CAGR) of 11.5% • Growth Driver: Impact Of Rising Diabetes Prevalence On The Growth Of The Peripheral Neuropathy Market • Market Trend: Technological Advancements In Peripheral Neuropathy Screening Enhanced Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Peripheral Neuropathy Market?

Peripheral neuropathy refers to a condition characterized by damage or dysfunction of the peripheral nerves, which transmit signals between the central nervous system (the brain and spinal cord) and the rest of the body. This disorder can cause various symptoms, including numbness, tingling, weakness, and pain, typically in the hands and feet. The main types of peripheral neuropathy are chemotherapy-induced, diabetic, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS-associated), idiopathic. Chemotherapy-induced refers to the adverse effects or conditions caused by chemotherapy treatment. The diagnosis includes blood test, biopsy, imaging, and others while treatment options such as medications, antidepressants, anti-seizure medication, pain relievers, topical treatment, therapies, nerve stimulation, plasma exchange, physical therapy, and others. The end users include hospitals, clinics, and ambulatory centers.

What Is The Peripheral Neuropathy Market Growth Forecast?

The peripheral neuropathy market size is expected to see rapid growth in the next few years. It will grow to $7.98 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to advancements in nerve stimulation therapies, increasing adoption of physical therapy and non-pharmacological treatments, growing availability of topical and systemic medications, rising use of online pharmacies and telemedicine, expansion of specialized clinics and ambulatory centers. Major trends in the forecast period include increasing adoption of ai-based diagnostic tools for peripheral neuropathy, rising integration of big data and cloud solutions in patient monitoring, growing use of genomics and precision medicine for peripheral neuropathy treatment, increasing deployment of iot-enabled wearable devices for nerve health, rising implementation of industry 4.0 technologies in neuropathy treatment devices.

Global Peripheral Neuropathy Market Segmentation

1) By Type: Chemotherapy-Induced, Diabetic, Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS Associated), Idiopathic 2) By Diagnosis: Blood Test, Biopsy, Imaging, Other Diagnosis 3) By Treatment: Medications, Antidepressants, Anti-Seizure Medication, Pain Reliever, Topical Treatment, Therapies, Nerve Stimulation, Plasma Exchange, Physical Therapy, Other Treatments 4) By End-User: Hospitals, Clinics, Ambulatory Centers Subsegments: 1) By Chemotherapy-Induced: Taxane-Induced Peripheral Neuropathy, Platinum-Based Drug-Induced Neuropathy, Other Chemotherapy-Induced Neuropathies 2) By Diabetic: Type 1 Diabetes-Induced Peripheral Neuropathy, Type 2 Diabetes-Induced Peripheral Neuropathy 3) By Human Immunodeficiency Virus (HIV) Or Acquired Immunodeficiency Syndrome (AIDS) Associated: HIV-Associated Peripheral Neuropathy, AIDS-Related Peripheral Neuropathy 4) By Idiopathic: Acute Idiopathic Neuropathy, Chronic Idiopathic Neuropathy

What Is The Driver Of The Peripheral Neuropathy Market?

The rising prevalence of diabetes is expected to propel the growth of the peripheral neuropathy market going forward. Diabetes refers to a chronic condition characterized by high levels of glucose in the blood due to the body's inability to produce or effectively use insulin. The rising prevalence of diabetes is primarily due to factors such as increasing rates of obesity, sedentary lifestyles, and aging populations. Diabetes can cause peripheral neuropathy by damaging nerves due to prolonged high blood sugar levels, leading to symptoms like pain, tingling, and numbness in the extremities. Effective blood sugar management is crucial to prevent or slow the progression of this complication. For instance, in 2024, according to the International Diabetes Federation, a Belgium-based diabetes research organization, published that the number of adults aged 20 to 79 years living with diabetes worldwide is projected to increase significantly from about 589 million in 2024 to 853 million by 2050, representing a 45% increase. Therefore, the rising prevalence of diabetes is driving the growth of the peripheral neuropathy industry.

Key Players In The Global Peripheral Neuropathy Market

Major companies operating in the peripheral neuropathy market are Pfizer Inc., Merck and Co. Inc., Novartis AG, Bristol Myers Squibb Co, AstraZeneca Plc, Abbott Laboratories, Eli Lilly and Co., Daiichi Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Cipla Ltd., Apotex Inc, Hikma Pharmaceuticals PLC, Lupin Limited, Grunenthal GmbH, Lexicon Pharmaceuticals, Johnson and Johnson, Teva Pharmaceutical Industries Ltd, Sanofi, GSK plc

Global Peripheral Neuropathy Market Trends and Insights

Major companies operating in the peripheral neuropathy market are focused on developing advanced solutions, such as point-of-care devices, to improve the diagnosis and management of the condition. A point-of-care peripheral neuropathy quantitative screening test is a diagnostic tool used to rapidly detect the presence of nerve damage in the extremities of individuals, particularly those with diabetes. For instance, in January 2023, NeuroMetrix Inc., a US-based non-invasive medical device manufacturer, launched the DPNCheck 2.0 point-of-care device for detecting peripheral neuropathy. The device uses nerve conduction technology to detect the systemic degeneration of peripheral nerves, which can lead to debilitating conditions such as diabetic peripheral neuropathy (DPN). It offers rapid patient screening through quantitative peripheral nerve function measurement, making it a more efficient and accurate tool compared to traditional methods such as monofilament and tuning fork tests.

What Are Latest Mergers And Acquisitions In The Peripheral Neuropathy Market?

In May 2024, Lexicon Pharmaceuticals, a US-based biopharma company specializing in novel therapies for neuropathic pain, partnered with Medidata Solutions, Inc., to advance its Phase 2b progress study of LX9211 (pilavapadin) and target diabetic peripheral neuropathic pain (DPNP). This collaboration streamlines the clinical development of LX9211, a novel non-opioid AAK1 inhibitor, by leveraging Medidata’s decentralized trial platform and real-time data capture, thereby improving patient experience and speeding up enrollment and trial execution. Medidata Solutions, Inc. is a US-based technology and software company specializing in cloud-based solutions for clinical trials and life sciences research.

Regional Outlook

North America was the largest region in the peripheral neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Peripheral Neuropathy Market?

The peripheral neuropathy market consists of revenues earned by entities by providing services such as neurological evaluation, pain management, physical therapy, occupational therapy, podiatry services, orthopedic support, nutritional counseling, psychological support, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral neuropathy market also includes sales of pain relief creams, orthopedic shoes, compression socks, tens devices, foot care kits, braces and supports, nutritional supplements, mobility aids, and assistive devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Peripheral Neuropathy Market Report 2026?

The peripheral neuropathy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral neuropathy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.